Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Serri

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
Neuro-Chirurgie|January 1, 1981
[In vitro studies of prolactinomas]N Duhamel-Maestracci, O Serri
The Journal of Clinical Endocrinology and Metabolism|July 1, 1981
Effects of naloxone on insulin-induced release of pituitary hormonesO Serri, E Rasio, M Somma
The New England Journal of Medicine|October 28, 1993
Relapse of hyperprolactinemia revisitedO Serri, J Hardy, F Massoud
Current Therapy in Endocrinology and Metabolism|January 1, 1994
ProlactinomaO Serri, H Beauregard, M Somma
Hormone Research|January 1, 1985
Effects of alloxan-induced diabetes on dopaminergic receptors in rat striatum and anterior pituitaryO Serri, G Renier, M Somma
Metabolism: Clinical and Experimental|October 1, 1989
Effect of dietary restriction and repeated growth hormone-releasing factor injections on growth hormone response to growth hormone-releasing factor in obese subjectsI Csizmadi, P Brazeau, O Serri
Neuroendocrinology|May 1, 1987
Dual action of dopamine on growth hormone release in vitroO Serri, N Deslauriers, P Brazeau
Metabolism: Clinical and Experimental|October 10, 1997
Gliclazide decreases cell-mediated low-density lipoprotein (LDL) oxidation and reduces monocyte adhesion to endothelial cells induced by oxidatively modified LDLA C Desfaits, O Serri, G Renier
Diabetes Care|May 8, 1998
Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatmentA C Desfaits, O Serri, G Renier
Hypertension (Dallas, Tex. : 1979)|September 1, 1982
Sulfoconjugation of catecholamines, nutrition, and hypertensionO Kuchel, N T Buu, O Serri
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Neuro-Chirurgie|January 1, 1981
[In vitro studies of prolactinomas]N Duhamel-Maestracci, O Serri
The Journal of Clinical Endocrinology and Metabolism|July 1, 1981
Effects of naloxone on insulin-induced release of pituitary hormonesO Serri, E Rasio, M Somma
The New England Journal of Medicine|October 28, 1993
Relapse of hyperprolactinemia revisitedO Serri, J Hardy, F Massoud
Current Therapy in Endocrinology and Metabolism|January 1, 1994
ProlactinomaO Serri, H Beauregard, M Somma
Hormone Research|January 1, 1985
Effects of alloxan-induced diabetes on dopaminergic receptors in rat striatum and anterior pituitaryO Serri, G Renier, M Somma
Metabolism: Clinical and Experimental|October 1, 1989
Effect of dietary restriction and repeated growth hormone-releasing factor injections on growth hormone response to growth hormone-releasing factor in obese subjectsI Csizmadi, P Brazeau, O Serri
Neuroendocrinology|May 1, 1987
Dual action of dopamine on growth hormone release in vitroO Serri, N Deslauriers, P Brazeau
Metabolism: Clinical and Experimental|October 10, 1997
Gliclazide decreases cell-mediated low-density lipoprotein (LDL) oxidation and reduces monocyte adhesion to endothelial cells induced by oxidatively modified LDLA C Desfaits, O Serri, G Renier
Diabetes Care|May 8, 1998
Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatmentA C Desfaits, O Serri, G Renier
Hypertension (Dallas, Tex. : 1979)|September 1, 1982
Sulfoconjugation of catecholamines, nutrition, and hypertensionO Kuchel, N T Buu, O Serri
Pageof 6